Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review.

By E. Balk, A. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, Joseph Lau. Atherosclerosis, 2006

749 citations recorded by the source corpus.

Subfields: Biochemistry, Endocrinology, Diabetes and Metabolism, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/d091b65768ce4fbe0d1931fdc0ecd64937eb7c86

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biochemistry

1. G. Barceló-Coblijn
2. E. Murphy

In Endocrinology, Diabetes and Metabolism

1. Veronica Graham

In Nutrition and Dietetics

1. G. Barceló-Coblijn
2. E. Murphy
3. Veronica Graham

Citations in the corpus

• Fatty acid composition of wild edible mushrooms species: A comparative study (2009, background): “Since humans are limited in the obtainment of EPA from linolenic acid, they need a supplementary diet intake to maintain the recommended levels of this acid in the organism [33].”
• Australian Dietary Guidelines (2006, background): “Cardiovascular disease: Of the systematic reviews addressing the risk of cardiovascular disease and consumption of fats and oils [410, 491-499], only one review [410] focused on the proportions of dietary fatty acids in the overall diet rather than the effects of omega-3 fatty acids on markers of ca”
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, methodology): “6 mmol/L (496 mg/dL).(135) Although a recent Japanese study in patients with hypercholesterolaemia reported a 19% reduction in CVD outcome,(136) the data remain inconclusive(137) and their clinical efficacy appears to be related to non-lipid effects.”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, neutral): “More detailed data on clinical outcomes are needed to justify the use of prescription n-3 fatty acids.(280) The recommended doses of total EPA and DHA to lower TGs have varied between 2 and 4 g/day.”
• Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. (2009, background): “is influenced by the baseline plasma TAG level of the subjects [210].”